IGC Pharma (IGC) Investor presentation summary

Strategic positioning and market opportunity

• Focused on Alzheimer's therapeutics and complementary & alternative medicine, targeting markets projected to reach $15.2B and $1.2T, respectively, by 2030 and 2033.

• Diversified pipeline includes multiple patent-protected Alzheimer's candidates and new GLP-1 candidates for metabolic disorders.

• Expansion into GLP-1 therapies leverages AI-driven insights for weight management and type-2 diabetes.

• Vertically integrated manufacturing and clean capital structure support growth.

• Leading AI partnerships and development of an Alzheimer's foundation model for early diagnosis.

Clinical development and pipeline

• IGC-AD1 is in Phase 2 CALMA trial for agitation in Alzheimer's, with 50 of 146 patients enrolled.

• Interim results show IGC-AD1 outperforms current approved therapy (brexpiprazole) in reducing agitation, with a large effect size and no serious adverse events reported.

• Preclinical data indicate IGC-AD1 inhibits amyloid plaque production by ~40% and improves spatial memory in mouse models.

• Additional assets in preclinical and toxicology studies target amyloid plaques, tau aggregation, and GLP-1/GIP pathways.

• TGR-63, licensed from JNCASR, shows potential to reduce amyloid burden and rescue neuronal cells in preclinical AD models.

Intellectual property and scientific leadership

• 32 patent applications filed across the US, Canada, Europe, and other regions, with 8 US and 4 foreign patents granted.

• Patents cover compositions and methods for CNS disorders, cancer, epilepsy, eating disorders, and pain management.

• Scientific advisory board includes experts from leading institutions such as Howard University, USF, JNCASR, and Max Planck Institute.

• Internal CRO and partnerships with top universities for AI and animal studies.